The FDA recently admonished Fresenius, a large national dialysis chain, for failing to disclose warnings to its providers about proper monitoring of serum bicarbonate levels before dialysis is administered. The FDA referred to a November 2011 internal memo from Fresienus’ Medical Office discussing the risk, which was not shared with providers of the chain, thereby exposing patients to a 6 to 8 fold increased risk of cardiopulmonary arrest and sudden cardiac death from dialysis.
Have you or a loved one received dialysis from a Fresenius treatment facility and suffered from:
- Cardiopulmonary Arrest
- Heart Attack
- Metabolic Alkalosis
- Sudden Cardiac Death
You may be entitled to compensation. Call the experienced attorneys at Andrews Thornton Higgins Razmara today at 1-800-664-1734.